Pacific Biosciences of California (NASDAQ:PACB) Insider Oene Mark Van Sells 55,107 Shares of Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Oene Mark Van sold 55,107 shares of Pacific Biosciences of California stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.63, for a total value of $89,824.41. Following the sale, the insider directly owned 1,742,638 shares in the company, valued at $2,840,499.94. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Oene Mark Van also recently made the following trade(s):

• On Tuesday, February 17th, Oene Mark Van sold 129,790 shares of Pacific Biosciences of California stock. The stock was sold at an average price of $1.58, for a total transaction of $205,068.20.

Pacific Biosciences of California Stock Down 5.1%

PACB traded down $0.09 during midday trading on Friday, hitting $1.60. The company had a trading volume of 1,762,429 shares, compared to its average volume of 8,036,723. The company has a quick ratio of 5.40, a current ratio of 6.24 and a debt-to-equity ratio of 17.88. Pacific Biosciences of California, Inc. has a 52 week low of $0.85 and a 52 week high of $2.73. The stock’s 50 day moving average price is $2.02 and its 200 day moving average price is $1.77. The company has a market capitalization of $481.55 million, a price-to-earnings ratio of -0.87 and a beta of 2.27.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. Pacific Biosciences of California had a negative net margin of 341.47% and a negative return on equity of 251.75%. The firm had revenue of $44.65 million during the quarter, compared to analyst estimates of $44.60 million. On average, research analysts anticipate that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on PACB. Barclays boosted their target price on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Piper Sandler lifted their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Stephens raised their price objective on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.20.

Institutional Trading of Pacific Biosciences of California

Large investors have recently bought and sold shares of the company. Amiral Gestion acquired a new position in shares of Pacific Biosciences of California in the 2nd quarter valued at about $3,208,000. Geode Capital Management LLC raised its stake in Pacific Biosciences of California by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock valued at $8,333,000 after acquiring an additional 401,637 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Pacific Biosciences of California by 95.5% in the second quarter. XTX Topco Ltd now owns 954,596 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 466,359 shares in the last quarter. Carret Asset Management LLC acquired a new stake in Pacific Biosciences of California in the 2nd quarter valued at about $391,000. Finally, Financial Advocates Investment Management bought a new position in shares of Pacific Biosciences of California in the second quarter valued at $50,000.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Neutral Sentiment: PacBio will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026 — management will do a fireside chat that could provide updated guidance or color on product adoption and commercialization plans. Read More.
• Negative Sentiment: Christian O. Henry sold 331,793 shares on Feb. 17 (avg $1.58) and 140,874 shares on Feb. 18 (avg $1.63) — combined ~472,667 shares for roughly $753,858 in proceeds; each sale reduced his reported ownership (SEC filings). Insider selling at this scale often weighs on sentiment. Read More.
• Negative Sentiment: Oene Mark Van sold 129,790 shares on Feb. 17 (avg $1.58) and 55,107 shares on Feb. 18 (avg $1.63) — total ~184,897 shares (~$294,893). These reductions in his stake were disclosed to the SEC and can pressure the stock. Read More.
• Negative Sentiment: Michele Farmer sold 35,215 shares on Feb. 17 (avg $1.58) and 14,952 shares on Feb. 18 (avg $1.63) — total ~50,167 shares (~$80,011). Her filings show notable reductions in ownership. Read More.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.